Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Elon Musk revealed that he uses the weight-loss drug Mounjaro and praises it for having fewer side effects than Ozempic.

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to ...